IER3 Antikörper (AA 85-156) (Cy3)
Kurzübersicht für IER3 Antikörper (AA 85-156) (Cy3) (ABIN901748)
Target
Alle IER3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 85-156
-
Kreuzreaktivität
- Ratte
-
Homologie
- Human,Mouse,Dog,Cow,Sheep,Pig,Horse,Rabbit
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human IEX1/Differentiation dependent gene 2 protein
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- IER3 (Immediate Early Response 3 (IER3))
-
Andere Bezeichnung
- IEX1
-
Hintergrund
-
Synonyms: DIF2, IEX1, PRG1, DIF-2, GLY96, IEX-1, IEX-1L, Radiation-inducible immediate-early gene IEX-1, Differentiation-dependent gene 2 protein, Protein DIF-2, Immediate early protein GLY96, Immediate early response 3 protein, PACAP-responsive gene 1 protein, Protein PRG1, IER3
Background: May play a role in the ERK signaling pathway by inhibiting the dephosphorylation of ERK by phosphatase PP2A-PPP2R5C holoenzyme. Acts also as an ERK downstream effector mediating survival. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment.
-
Gen-ID
- 8870
-
UniProt
- P46695
-
Pathways
- Regulation of Carbohydrate Metabolic Process
Target
-